menu
    • menu
    [{"orgOrder":0,"company":"Angitia Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"AGA2118","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Angitia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Angitia Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Angitia Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Angitia Biopharmaceuticals","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2024","type":"Series C Financing","leadProduct":"AGA2118","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Angitia Biopharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.12,"dosageForm":"","sponsorNew":"Angitia Biopharmaceuticals \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Angitia Biopharmaceuticals \/ Bain Capital Life Sciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Angitia Biopharmaceuticals

    Menu

    Angitia Biopharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Angitia Biopharmaceuticals

                            China arrow
                            Pittcon 2025
                            Not Confirmed

                            Angitia Biopharmaceuticals

                            China arrow
                            Pittcon 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGA2118

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Bain Capital Life Sciences

                            Deal Size : $120.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Angitia Biopharmaceuticals Announces $120 Million Series C Financing

                            Details : The financing will enable Angitia to advance AGA2118 & AGA2115, bispecific antibodies targeting sclerostin and DKK1, through clinical development for the treatment of osteoporosis & OI, respectively.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 11, 2024

                            Lead Product(s) : AGA2118

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Bain Capital Life Sciences

                            Deal Size : $120.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Angitia Biopharmaceuticals

                            China arrow
                            Pittcon 2025
                            Not Confirmed

                            Angitia Biopharmaceuticals

                            China arrow
                            Pittcon 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGA2118

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Angitia Doses First Patient in Phase 2 Trial of AGA2118 for Osteoporosis

                            Details : AGA2118 is a bispecific antibody that targets sclerostin and DKK1 and is in clinical development for treating patients with postmenopausal osteoporosis.

                            Product Name : AGA2118

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 04, 2024

                            Lead Product(s) : AGA2118

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth